Skip to content

Study · Other design · 2025

6 results

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.

Hankosky ER, He X, Malik R, Fraseur Brumm J, Wang F, Niemeyer A, Zhang XM, Garvey WT

Diabetes, obesity & metabolism5 May 2025Cited by 11 (Europe PMC)

PMID40321113 (opens in a new tab)PMCIDPMC12146454 (opens in a new tab)DOI10.1111/dom.16401 (opens in a new tab)PepBankPUB-40321113
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanOther designEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, an indirect comparison estimated that tirzepatide 10 mg reduced body weight by 2.57 percentage points more than semaglutide 2.4 mg (p < 0.01).

    In plain wordsIn adults with obesity and type 2 diabetes, an indirect comparison found tirzepatide 10 mg gave more weight loss than semaglutide 2.4 mg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean percent weight change vs semaglutide, tirzepatide 10 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 2.4 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean difference in weight change
    2.57%
    10 mg vs semaglutide 2.4 mg

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with significantly greater mean percent weight reductions versus semaglutide (mean difference, 10 mg: 2.57%; 15 mg: 4.79%, p < 0.01).
    1 context sentence
    Summary · context
    Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT-2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand.
  2. 02HumanOther designEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, an indirect comparison estimated that tirzepatide 15 mg reduced body weight by 4.79 percentage points more than semaglutide 2.4 mg (p < 0.01).

    In plain wordsIn adults with obesity and type 2 diabetes, an indirect comparison found tirzepatide 15 mg gave more weight loss than semaglutide 2.4 mg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean percent weight change vs semaglutide, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 2.4 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean difference in weight change
    4.79%
    15 mg vs semaglutide 2.4 mg

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with significantly greater mean percent weight reductions versus semaglutide (mean difference, 10 mg: 2.57%; 15 mg: 4.79%, p < 0.01).
    1 context sentence
    Summary · context
    Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT-2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand.
  3. 03HumanOther designEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, an indirect comparison found tirzepatide 15 mg had significantly higher odds of at least 5% weight reduction than semaglutide 2.4 mg (odds ratio 1.76).

    In plain wordsIn adults with obesity and diabetes, an indirect comparison found 5% weight loss more likely with tirzepatide 15 mg than semaglutide 2.4 mg.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight reduction of at least 5%, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 2.4 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · 72 weeksAs given in this study (human).

    Measurements

    Odds ratio for >=5% weight reduction
    1.76
    15 mg vs semaglutide 2.4 mg

    Source sentences

    Summary
    Tirzepatide 15 mg had significantly higher odds of achieving ≥5% weight reduction (odds ratio 15 mg: 1.76, 95% CI 1.04-2.97, p = 0.035
    1 context sentence
    Summary · context
    Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT-2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand.
  4. 04HumanOther designEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, an indirect comparison found no significant difference between tirzepatide 10 mg and semaglutide 2.4 mg in the odds of at least 5% weight reduction (odds ratio 1.24).

    In plain wordsIn adults with obesity and diabetes, an indirect comparison found no clear difference in 5% weight loss between tirzepatide 10 mg and semaglutide 2.4 mg.

    Peptide
    Tirzepatide
    Outcome
    No significant changeWeight reduction of at least 5%, tirzepatide 10 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 2.4 mg
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · 72 weeksAs given in this study (human).

    Measurements

    Odds ratio for >=5% weight reduction
    1.24
    10 mg vs semaglutide 2.4 mg

    Source sentences

    Summary
    odds ratio 10 mg: 1.24, 95% CI 0.75-2.04, p = 0.407
    1 context sentence
    Summary · context
    Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT-2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand.
  5. 05HumanOther designEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, an indirect comparison estimated that tirzepatide 10 mg reduced HbA1c by 0.47 percentage points more than semaglutide 2.4 mg (p < 0.001).

    In plain wordsIn adults with obesity and type 2 diabetes, an indirect comparison found tirzepatide 10 mg lowered HbA1c more than semaglutide 2.4 mg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change vs semaglutide, tirzepatide 10 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 2.4 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean difference in HbA1c change
    0.47%
    10 mg vs semaglutide 2.4 mg

    Source sentences

    Summary
    both tirzepatide doses were associated with significantly greater reductions in HbA1c (%) levels (mean difference, 10 mg: 0.47%; 15 mg: 0.56%, p < 0.001
    1 context sentence
    Summary · context
    Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT-2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand.
  6. 06HumanOther designEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, an indirect comparison estimated that tirzepatide 15 mg reduced HbA1c by 0.56 percentage points more than semaglutide 2.4 mg (p < 0.001).

    In plain wordsIn adults with obesity and type 2 diabetes, an indirect comparison found tirzepatide 15 mg lowered HbA1c more than semaglutide 2.4 mg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change vs semaglutide, tirzepatide 15 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 2.4 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 72 weeksAs given in this study (human).

    Measurements

    Mean difference in HbA1c change
    0.56%
    15 mg vs semaglutide 2.4 mg

    Source sentences

    Summary
    both tirzepatide doses were associated with significantly greater reductions in HbA1c (%) levels (mean difference, 10 mg: 0.47%; 15 mg: 0.56%, p < 0.001
    1 context sentence
    Summary · context
    Mean percent change in weight from baseline, weight reduction ≥5% and mean change in glycated haemoglobin (HbA1c [%]) were compared between tirzepatide 10/15 mg (week 72, SURMOUNT-2) and semaglutide 2.4 mg (week 68, STEP 2) applying the Bucher method to the efficacy estimand.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.